Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Labcyte and Deerac Fluidics Combine Forces to Enhance Low Volume Liquid Handling

Published: Wednesday, January 30, 2008
Last Updated: Wednesday, January 30, 2008
Bookmark and Share
Labcyte and Allegro Technologies Limited have reached agreement on the terms for combination of the two companies.

Labcyte Inc. and Allegro Technologies Limited, which conducts business as Deerac Fluidics, announced that they have reached agreement on the terms for combination of the two companies. Completion of the transaction requires shareholder approval and is expected within one month.

As pharmaceutical companies, genomic service providers, and other life science research organizations desire to perform larger numbers of assays within fixed budgets, there is a strong drive to reduce the volume of each assay in order to reduce cost and minimize waste.

According to both companies, although products from both Labcyte and Deerac address the growing market of low-volume liquid handling, each company utilizes a unique technology and they operate in different volume ranges. Products from Labcyte and Deerac are used for different applications. They may also be used together when one component of an assay is added in the low nanoliter range and others are added in larger amounts.

The Deerac products are based on a patented feed-back controlled system which effective in the 50 nanoliter to 20 microliter range. This technology was conceived at Trinity College Dublin, and its development was supported by grants from Enterprise Ireland.

The Labcyte Echo ® liquid handlers use acoustic energy to transfer 2.5 nanoliter droplets and are most useful in the 2.5 to 200 nanoliter range.

“At Labcyte, we evaluated a wide variety of low-volume liquid handlers and found the Deerac Latitude™ and Equator™ to have the best precision in the 50 nanoliter range. We also found that the speed and flexibility of the Latitude could double the throughput of our new POD™ 810 plate assembler for assay plate preparation. The two teams have also conducted several joint seminars on low-volume assays and our people work well together,” said Dr. Elaine J. Heron, Chief Executive Officer of Labcyte. “It became clear that it made sense to combine the two companies.”

“Having research and manufacturing groups in Dublin gives us a solid base from which to support our growing business in Europe,” continued Dr. Heron. “Dublin offers a vibrant research community with business-friendly policies. The innovative atmosphere created by Trinity College Dublin makes location of our European operations close by especially attractive.”

“We are excited to become part of the business that has brought acoustic droplet ejection from a concept to a mainstream product used by most pharmaceutical companies,” said Dr. Jurgen Osing, the Managing Director of Deerac Fluidics, “and we are anxious to use our expertise in genomics to expand the applications of Labcyte Echo systems. This is also an opportunity for providing more local support for the Latitude and Equator products.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
The Need for Speed
Evaluating MALDI-TOF as a high-throughput screening technology for the pharmaceutical industry.
Antarctic Sponge Extract Kills MRSA
New findings may provide opportunity for developing new drugs to fight dangerous bacteria currently highly resistant to treatment.
US-India Collab Finds Molecular Signatures of Severe Malaria
Study may be a significant advancement in understanding the causes of severe malaria.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
Gene Expression Controls Revealed
Researchers have modelled every atom in a key part of the process for switching on genes, revealing a whole new area for potential drug targets.
An Old-New Weapon Against Emerging Chikungunya Virus
Researchers utilize existing drugs to interfere with host factors required for replication of Chikungunya virus.
Using Gene-editing Technology for Faster, Cheaper Antiviral Drug Development
UCLA scientists are working to develop special screening libraries based on a gene-editing technology called CRISPR.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!